Acute rejection or side effects occur in nearly half of all transplant patients receiving immunosuppression. During our studies with regimens of (SRL) sirolimus+cyclosporine/tacrolimus (CsA/TAC), cytokine and costimulatory cell surface proteins (biomarkers), have demonstrated sensitivity to clinically relevant immunosuppressive drug concentrations in mitogen-stimulated peripheral blood lymphocytes (PBL) from normal and transplanted human subjects. Effect: concentration (pharmacodynamic, PD) relationships between biomarkers and drug concentrations also indicate ability to measure single- and multiple-agent effects within combination regiments, and to predict the amount of drug needed to inhibit a certain amount of biomarker, both for patient populations and individuals. However, prior to use as measures of immunosuppressive effect, the amount of biomarker inhibition associated with clinical conditions representing insufficient, excessive and adequate immunosuppression must be known. This may define safe amounts of drugs for children, who experience a higher incidence of life-threatening complications of immunosuppression such as post-transplant lymphoproliferative disorder. Therefore, the specific aim of this project is to measure biomarker expression during a planned pharmacokinetic (PK) evaluation of a SRL+TAC regimen in 40 children with liver transplants, relate it to amount of drug, and to determine whether the occurrence of acute rejection, side effects and stable post-transplant course can be related to threshold levels of biomarker inhibition or the amount of drug associated with such thresholds. During a sponsored clinical trial of SRL+TAC, our proposal will manage biomarker data as follows: 1. Measure mitogen-stimulated expression of the cytokines IL-2, TNF-alpha and IFN-gamma in T-cells, and of costimulatory proteins CD54 (intercellular adhesion molecule-1), CD86 (B7.2) and CD95 (Fas antigen) in B-cells, and the proliferative response of lymphocytes to donor antigen. This will be performed during PK studies planned in the clinical trial, and additionally, during rejection, side effects, and at 12, and 24 month after transplantiation. 2. PD modeling to predict biomarker thresholds or drug concentrations associated with them, which are related to the occurrence of acute rejection, side effects, and the stable post-transplant course. Potential benefits may include customized regimens in the future, and decreased complications in one-half of the nearly 40,000 new transplant recipients of solid organ and bone marrow grafts, each year.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI049156-02
Application #
6555805
Study Section
Special Emphasis Panel (ZRG1-SSS-J (06))
Program Officer
Bridges, Nancy D
Project Start
2001-09-04
Project End
2005-05-31
Budget Start
2002-07-01
Budget End
2003-05-31
Support Year
2
Fiscal Year
2002
Total Cost
$232,750
Indirect Cost
Name
Children's Hosp Pittsburgh/Upmc Health Sys
Department
Type
DUNS #
044304145
City
Pittsburgh
State
PA
Country
United States
Zip Code
15224
Sindhi, Rakesh; Ashokkumar, Chethan; Higgs, Brandon W (2011) Cellular alloresponses for rejection-risk assessment after pediatric transplantation. Curr Opin Organ Transplant 16:515-21
Ashokkumar, C; Talukdar, A; Sun, Q et al. (2009) Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant 9:179-91
Ashokkumar, Chethan; Sun, Qing; Gupta, Ankit et al. (2009) Proliferative alloresponse of T-cytotoxic cells identifies rejection-prone children with steroid-free liver transplantation. Liver Transpl 15:978-85
Gupta, Ankit; Kumar, Chethan Ashok; Ningappa, Mylarappa et al. (2009) Elevated myeloid: plasmacytoid dendritic cell ratio associates with late, but not early, liver rejection in children induced with rabbit anti-human thymocyte globulin. Transplantation 88:589-94
Talukdar, Anjan; AshokKumar, Chethan; Farrar, Jennifer et al. (2008) Lymphocyte subset reconstitution in pediatric liver recipients induced with steroid-free rabbit anti-human thymocyte globulin. Pediatr Transplant 12:804-8
Khera, Nandita; Janosky, Janine; Zeevi, Adriana et al. (2007) Persistent donor-specific alloreactivity may portend delayed liver rejection during drug minimization in children. Front Biosci 12:660-3
Berry, Vishal; Magill, Amy; Yost, Mary et al. (2006) Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses. Cytometry A 69:95-103
Sindhi, Rakesh; Magill, Amy; Bentlejewski, Carol et al. (2005) Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. Am J Transplant 5:96-102
Sindhi, Rakesh; Manavalan, John Sanil; Magill, Amy et al. (2005) Reduced immunosuppression in pediatric liver-intestine transplant recipients with CD8+CD28- T-suppressor cells. Hum Immunol 66:252-7
Sindhi, Rakesh; Berry, Vishal; Janosky, Janine (2004) Multiparametric effect: concentration analyses. Front Biosci 9:1218-21